Several other analysts also recently weighed in on the company. Zacks Investment Research downgraded Hikma Pharmaceutic from a buy rating to a hold rating in a research report on Friday, March 17th. Jefferies Group LLC downgraded Hikma Pharmaceutic from a buy rating to an underperform rating in a report on Wednesday, May 17th. Finally, HSBC Holdings plc restated a reduce rating on shares of Hikma Pharmaceutic in a report on Friday, March 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Hikma Pharmaceutic currently has a consensus rating of Hold and a consensus price target of $27.00.
Shares of Hikma Pharmaceutic (OTC:HKMPF) opened at 25.35 on Friday. The firm has a market cap of $6.11 billion and a P/E ratio of 38.29. Hikma Pharmaceutic has a 52-week low of $20.43 and a 52-week high of $35.25. The firm’s 50-day moving average is $24.71 and its 200-day moving average is $23.80.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://sleekmoney.com/numis-securities-ltd-reaffirms-add-rating-for-hikma-pharmaceutic-hkmpf/1851347.html.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/numis-securities-ltd-reaffirms-add-rating-for-hikma-pharmaceutic-hkmpf/1851347.html
Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.